Posted On: 12/14/2013 10:38:32 AM
Post# of 94259
$NWBO Up to date company activities and other important information about $NWBO
$NWBO
DD Notes ~ http://www.ddnotesmaker.com/NWBO
##### recent news/filings ~ source: finance.yahoo.com
Fri, 13 Dec 2013 23:03:17 GMT ~ Nasdaq stocks posting largest volume increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************
Fri, 13 Dec 2013 23:02:55 GMT ~ Nasdaq stocks posting largest percentage increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************
Tue, 10 Dec 2013 13:15:00 GMT ~ First Interim Analysis Of NW Bio's Phase III GBM Trial Triggered By Reaching Required Number Of "Events"
- BETHESDA, Md., Dec. 10, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the number of events required to trigger the first interim analysis of its Phase III clinical trial in patients with Glioblastoma multiforme (GBM) brain cancer has been reached, and the analysis process is under way which will culminate in the independent Data Monitoring Committee's assessment. This important milestone is measured by "events," which are defined as either a tumor recurrence or a death. The pre-specified trigger number for this first interim analysis of NW Bio's international Phase III trial is 66 such events, comprising 60% of the 110 events required to reach the primary endpoint of the Phase III trial. Another interim analysis will occur when 88 events, comprising 80% of the total 110 events, have been reached.
read full: http://finance.yahoo.com/news/first-interim-a...00395.html
*********************************************************
Mon, 09 Dec 2013 14:29:44 GMT ~ Northwest Biotherapeutics: An Analysis Of Its Transforming Balance Sheet Restructuring
read full: http://seekingalpha.com/article/1885731-north...urce=yahoo
*********************************************************
Thu, 05 Dec 2013 13:15:00 GMT ~ Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
- BETHESDA, Md., Dec. 5, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda F. Powers will present at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10th and 11th at the Crowne Plaza Hotel in New York City. The Company will present on Tuesday, December 10, 2013, at 1:35 p.m. Investors interested in meeting one-on-one with senior management during the conference should contact their Oppenheimer representative or the Company. Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.
read full: http://finance.yahoo.com/news/northwest-bioth...00341.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=NWBO&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=NWBO&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NWBO/company-info
Ticker: $NWBO
OTC Market Place: Not Available
CIK code: 0001072379
Company name: Northwest Biotherapeutics, Inc.
Company website: http://www.nwbio.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/NWBO/filings
Latest financials: http://www.otcmarkets.com/stock/NWBO/financials
Latest news: http://www.otcmarkets.com/stock/NWBO/news - http://finance.yahoo.com/q/h?s=NWBO+Headlines
Major holdings: http://data.cnbc.com/quotes/NWBO/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=NWBO+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/NWBO.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=NWBO
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Northwest+Biothera...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.nwbio.com
Alexa: http://www.alexa.com/siteinfo/http://www.nwbio.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.nwbio.com
http://www.pennystocktweets.com/stocks/profile/NWBO
##### last known share structure ~ source: otcmarkets.com
Market Value: $137,472,400 a/o Dec 13, 2013
Shares Outstanding: 38,507,675 a/o Nov 12, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
##### business description ~ source: otcmarkets.com
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA.
DD Notes ~ http://www.ddnotesmaker.com/NWBO
$NWBO
DD Notes ~ http://www.ddnotesmaker.com/NWBO
##### recent news/filings ~ source: finance.yahoo.com
Fri, 13 Dec 2013 23:03:17 GMT ~ Nasdaq stocks posting largest volume increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************
Fri, 13 Dec 2013 23:02:55 GMT ~ Nasdaq stocks posting largest percentage increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************
Tue, 10 Dec 2013 13:15:00 GMT ~ First Interim Analysis Of NW Bio's Phase III GBM Trial Triggered By Reaching Required Number Of "Events"
- BETHESDA, Md., Dec. 10, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the number of events required to trigger the first interim analysis of its Phase III clinical trial in patients with Glioblastoma multiforme (GBM) brain cancer has been reached, and the analysis process is under way which will culminate in the independent Data Monitoring Committee's assessment. This important milestone is measured by "events," which are defined as either a tumor recurrence or a death. The pre-specified trigger number for this first interim analysis of NW Bio's international Phase III trial is 66 such events, comprising 60% of the 110 events required to reach the primary endpoint of the Phase III trial. Another interim analysis will occur when 88 events, comprising 80% of the total 110 events, have been reached.
read full: http://finance.yahoo.com/news/first-interim-a...00395.html
*********************************************************
Mon, 09 Dec 2013 14:29:44 GMT ~ Northwest Biotherapeutics: An Analysis Of Its Transforming Balance Sheet Restructuring
read full: http://seekingalpha.com/article/1885731-north...urce=yahoo
*********************************************************
Thu, 05 Dec 2013 13:15:00 GMT ~ Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
- BETHESDA, Md., Dec. 5, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda F. Powers will present at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10th and 11th at the Crowne Plaza Hotel in New York City. The Company will present on Tuesday, December 10, 2013, at 1:35 p.m. Investors interested in meeting one-on-one with senior management during the conference should contact their Oppenheimer representative or the Company. Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.
read full: http://finance.yahoo.com/news/northwest-bioth...00341.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=NWBO&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=NWBO&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NWBO/company-info
Ticker: $NWBO
OTC Market Place: Not Available
CIK code: 0001072379
Company name: Northwest Biotherapeutics, Inc.
Company website: http://www.nwbio.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/NWBO/filings
Latest financials: http://www.otcmarkets.com/stock/NWBO/financials
Latest news: http://www.otcmarkets.com/stock/NWBO/news - http://finance.yahoo.com/q/h?s=NWBO+Headlines
Major holdings: http://data.cnbc.com/quotes/NWBO/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=NWBO+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/NWBO.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=NWBO
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Northwest+Biothera...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.nwbio.com
Alexa: http://www.alexa.com/siteinfo/http://www.nwbio.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.nwbio.com
http://www.pennystocktweets.com/stocks/profile/NWBO
##### last known share structure ~ source: otcmarkets.com
Market Value: $137,472,400 a/o Dec 13, 2013
Shares Outstanding: 38,507,675 a/o Nov 12, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
##### business description ~ source: otcmarkets.com
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA.
DD Notes ~ http://www.ddnotesmaker.com/NWBO
(0)
(0)
